Research Paper|Volume 15, Issue 17|pp 8770—8781

Prognostic value of lactate dehydrogenase in patients with uveal melanoma treated with immune checkpoint inhibition

Xiaocui Liang^1,², Shan Zhou^1,², Zefeng Xiao^1,²

¹Department of Ophthalmology, Wuhan No. 1 Hospital, Wuhan 430023, Hubei Province, China
²Department of Ophthalmology, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan 430023, Hubei Province, China

Received: May 8, 2023Accepted: July 19, 2023Published: September 5, 2023

https://doi.org/10.18632/aging.204996

Copyright: © 2023 Liang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: We performed the meta-analysis to explore the predictive value of lactate dehydrogenase (LDH) levels in uveal melanoma (UM) patients receiving immune checkpoint inhibitors (ICIs).

Methods: Eligible articles were obtained through EMBASE, PubMed, Google Scholar, and the Cochrane Library, until March 23, 2023. The clinical outcomes evaluated in this study encompassed overall survival (OS) and progression-free survival (PFS).

Results: This meta-analysis comprised eight studies with a combined total of 383 patients. The results showed that patients with high LDH levels had noticeably worse OS (HR: 3.445, 95% CI: 2.504-4.740, p < 0.001) and PFS (HR: 1.720, 95% CI: 1.429-2.070, p < 0.001). Subgroup analysis confirmed that the upper limit of normal was the ideal cut-off value for LDH. In multivariate analysis, we also found that high LDH levels significantly predicted shorter OS (HR: 3.405, 95% CI: 1.827-6.348, p < 0.001) and PFS (HR: 2.519, 95% CI: 1.557-4.076, p < 0.001) in UM patients. The sensitivity analysis and publication bias test supported the reliability of our results.

Conclusions: In UM patients treated with ICIs, the LDH levels were reliable indicators of prognosis.